Ersodetug (RZ358)
Congenital Hyperinsulinism (HI)
Key Facts
About Rezolute
Rezolute is a mission-driven, late-stage biotech dedicated to transforming the treatment landscape for hyperinsulinism (HI), a rare disease causing life-threatening hypoglycemia. Its lead asset, ersodetug, is a novel insulin receptor modulator with the potential to be a universal therapy across congenital and tumor-related HI forms. The company's strategy hinges on leveraging ersodetug's unique downstream mechanism and regulatory designations like Breakthrough Therapy to advance two Phase 3 registrational programs, aiming to deliver the first targeted therapy for hypoglycemia irrespective of its source.
View full company profileAbout Rezolute
Rezolute is a mission-driven, late-stage biotech dedicated to transforming the treatment landscape for hyperinsulinism (HI), a rare disease causing life-threatening hypoglycemia. Its lead asset, ersodetug, is a novel insulin receptor modulator with the potential to be a universal therapy across congenital and tumor-related HI forms. The company's strategy hinges on leveraging ersodetug's unique downstream mechanism and regulatory designations like Breakthrough Therapy to advance two Phase 3 registrational programs, aiming to deliver the first targeted therapy for hypoglycemia irrespective of its source.
View full company profileTherapeutic Areas
Other Congenital Hyperinsulinism (HI) Drugs
| Drug | Company | Phase |
|---|---|---|
| Avexitide | Amylyx Pharmaceuticals | Phase 2 |